Nivolumab 10 MG/ML

DRUG9 trials

Sponsors

Spanish Lung Cancer Group, GERCOR - Multidisciplinary Oncology Cooperative Group, Australasian Gastro-Intestinal Trials Group, Spanish Oncology Genito-Urinary Group, Bispebjerg Hospital

Conditions

Ablative Fractionated LaserBCC - Basal Cell CarcinomaColorectal Cancer MetastaticFollicular Lymphoma Stage IIFollicular Lymphoma Stage IIIFollicular Lymphoma Stage IVHodgkin LymphomaImmune Response

Early Phase 1

Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

Bispebjerg HospitalAblative Fractionated Laser, BCC - Basal Cell Carcinoma, Immune Response +1

Start: 2020-01-27End: 2021-11-30Target: 30Updated: 2020-09-30

Phase 2

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Active, not recruitingNCT03350126

GERCOR - Multidisciplinary Oncology Cooperative GroupMetastatic Cancer Colorectal

Start: 2017-12-04End: 2025-12-31Updated: 2025-07-23

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

CompletedNCT03647839

Australasian Gastro-Intestinal Trials GroupColorectal Cancer Metastatic

Start: 2018-09-06End: 2021-04-09Updated: 2021-08-27

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Spanish Oncology Genito-Urinary GroupMetastatic Hormone-sensitive Prostate Cancer

Start: 2019-02-11End: 2024-12-31Target: 135Updated: 2022-10-26

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Active, not recruitingNCT04006262

GERCOR - Multidisciplinary Oncology Cooperative GroupLocalized Oesogastric Adenocarcimona, MSI and or dMMR

Start: 2019-10-23End: 2025-10-31Target: 32Updated: 2025-06-15

Radiation Free Chemotherapy for Early Hodgkin Lymphoma

RecruitingNCT04866654

Medical University of GdanskHodgkin Lymphoma

Start: 2021-03-04End: 2026-07-02Target: 160Updated: 2021-08-12

Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION

TerminatedNCT04901988

The Christie NHS Foundation TrustMelanoma (Skin), Melanoma, Stage II

Start: 2021-11-08End: 2023-01-30Updated: 2025-02-27

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.

Active, not recruitingNCT05788081

Olivia Newton-John Cancer Research InstituteFollicular Lymphoma Stage II, Follicular Lymphoma Stage III, Follicular Lymphoma Stage IV

Start: 2023-08-31End: 2027-06-01Target: 40Updated: 2025-08-20

Unknown Phase

Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient

CompletedNCT03132493

Spanish Lung Cancer GroupNon Small Cell Lung Cancer

Start: 2017-06-01End: 2018-09-15Updated: 2018-11-14

Related Papers

Radiation-free therapy for the initial treatment of good prognosis early non-bulky HL, defined by a low metabolic tumor volume and a negative interim PET after 2 chemotherapy cycles. a phase II prospective rafting trial

Blood2025-11-03

Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study

Journal for ImmunoTherapy of Cancer2025-05-013 citations

Biological and therapeutic impact of tumor mutational burden in microsatellite instability/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI).

Journal of Clinical Oncology2025-01-271 citations

Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study

Blood Advances2025-01-073 citations

First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.

Journal of Clinical Oncology2024-06-012 citations

Trial in Progress: Treatment of Newly-Diagnosed Follicular Lymphoma with Celmod BMS-986369, Rituximab +/- Nivolumab: An Umbrella Phase II Investigator-Initiated Study

Blood2023-11-02

Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability.

2023-06-0132 citations

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Journal of Clinical Oncology2022-08-15334 citations

DETECTION phase II/III trial: Circulating tumor DNA–guided therapy for stage IIB/C melanoma after surgical resection.

Journal of Clinical Oncology2022-06-0111 citations

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

Journal of Clinical Oncology2022-01-1951 citations

One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.

Journal of Clinical Oncology2022-01-1919 citations

Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.

2021-05-1342 citations

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study

Journal for ImmunoTherapy of Cancer2020-11-0177 citations

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

2020-02-1013 citations

RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II study.

Journal of Clinical Oncology2020-02-011 citations

GECP 1605/NIVEX TRIAL nivolumab in the real world: The SPANISH expanded access program experience in pretreated advanced NSCLC

Annals of Oncology2018-10-011 citations